vs
Lucid Group, Inc.（LCID）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Lucid Group, Inc.的1.5倍（$772.1M vs $522.7M），Revvity净利率更高（12.7% vs -155.7%，领先168.5%），Lucid Group, Inc.同比增速更快（122.9% vs 5.9%），Revvity自由现金流更多（$161.8M vs $-1.2B），过去两年Lucid Group, Inc.的营收复合增速更高（74.0% vs 9.0%）
Lucid Group, Inc.是总部位于美国加利福尼亚州纽瓦克的汽车科技企业，专注于电动汽车制造及先进电动汽车动力系统供应。2021年9月，公司在亚利桑那州卡萨格兰德的工厂开始生产Lucid Air豪华轿车，第二款车型Lucid Gravity SUV于2024年12月投产，同时也为阿斯顿·马丁等其他车企供应和研发动力总成技术。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
LCID vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.5倍
$522.7M
营收增速更快
LCID
高出117.1%
5.9%
净利率更高
RVTY
高出168.5%
-155.7%
自由现金流更多
RVTY
多$1.4B
$-1.2B
两年增速更快
LCID
近两年复合增速
9.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $522.7M | $772.1M |
| 净利润 | $-814.0M | $98.4M |
| 毛利率 | -80.7% | — |
| 营业利润率 | -203.7% | 14.5% |
| 净利率 | -155.7% | 12.7% |
| 营收同比 | 122.9% | 5.9% |
| 净利润同比 | -104.9% | 3.9% |
| 每股收益（稀释后） | $-8.26 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LCIDRVTY
| Q4 25 | $522.7M | $772.1M | ||
| Q3 25 | $336.6M | $698.9M | ||
| Q2 25 | $259.4M | $720.3M | ||
| Q1 25 | $235.0M | $664.8M | ||
| Q4 24 | $234.5M | $729.4M | ||
| Q3 24 | $200.0M | $684.0M | ||
| Q2 24 | $200.6M | $691.7M | ||
| Q1 24 | $172.7M | $649.9M |
净利润LCIDRVTY
| Q4 25 | $-814.0M | $98.4M | ||
| Q3 25 | $-978.4M | $46.7M | ||
| Q2 25 | $-539.4M | $53.9M | ||
| Q1 25 | $-366.2M | $42.2M | ||
| Q4 24 | $-397.2M | $94.6M | ||
| Q3 24 | $-992.5M | $94.4M | ||
| Q2 24 | $-643.4M | $55.4M | ||
| Q1 24 | $-680.9M | $26.0M |
毛利率LCIDRVTY
| Q4 25 | -80.7% | — | ||
| Q3 25 | -99.1% | 53.6% | ||
| Q2 25 | -105.0% | 54.5% | ||
| Q1 25 | -97.2% | 56.5% | ||
| Q4 24 | -89.0% | — | ||
| Q3 24 | -106.2% | 56.3% | ||
| Q2 24 | -134.5% | 55.7% | ||
| Q1 24 | -134.3% | 54.6% |
营业利润率LCIDRVTY
| Q4 25 | -203.7% | 14.5% | ||
| Q3 25 | -279.9% | 11.7% | ||
| Q2 25 | -309.5% | 12.6% | ||
| Q1 25 | -294.4% | 10.9% | ||
| Q4 24 | -312.6% | 16.3% | ||
| Q3 24 | -385.2% | 14.3% | ||
| Q2 24 | -392.6% | 12.4% | ||
| Q1 24 | -422.6% | 6.8% |
净利率LCIDRVTY
| Q4 25 | -155.7% | 12.7% | ||
| Q3 25 | -290.7% | 6.7% | ||
| Q2 25 | -207.9% | 7.5% | ||
| Q1 25 | -155.8% | 6.4% | ||
| Q4 24 | -169.4% | 13.0% | ||
| Q3 24 | -496.1% | 13.8% | ||
| Q2 24 | -320.8% | 8.0% | ||
| Q1 24 | -394.2% | 4.0% |
每股收益（稀释后）LCIDRVTY
| Q4 25 | $-8.26 | $0.86 | ||
| Q3 25 | $-3.31 | $0.40 | ||
| Q2 25 | $-0.28 | $0.46 | ||
| Q1 25 | $-0.24 | $0.35 | ||
| Q4 24 | $-0.20 | $0.77 | ||
| Q3 24 | $-0.41 | $0.77 | ||
| Q2 24 | $-0.34 | $0.45 | ||
| Q1 24 | $-0.30 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $717.3M | $7.3B |
| 总资产 | $8.4B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LCIDRVTY
| Q4 25 | $1.6B | $919.9M | ||
| Q3 25 | $2.3B | $931.4M | ||
| Q2 25 | $2.8B | $991.8M | ||
| Q1 25 | $3.6B | $1.1B | ||
| Q4 24 | $4.0B | $1.2B | ||
| Q3 24 | $3.5B | $1.2B | ||
| Q2 24 | $3.2B | $2.0B | ||
| Q1 24 | $4.0B | $1.7B |
股东权益LCIDRVTY
| Q4 25 | $717.3M | $7.3B | ||
| Q3 25 | $1.8B | $7.4B | ||
| Q2 25 | $2.4B | $7.6B | ||
| Q1 25 | $3.2B | $7.6B | ||
| Q4 24 | $3.9B | $7.7B | ||
| Q3 24 | $2.7B | $7.9B | ||
| Q2 24 | $3.5B | $7.9B | ||
| Q1 24 | $4.2B | $7.8B |
总资产LCIDRVTY
| Q4 25 | $8.4B | $12.2B | ||
| Q3 25 | $8.8B | $12.1B | ||
| Q2 25 | $8.9B | $12.4B | ||
| Q1 25 | $9.2B | $12.4B | ||
| Q4 24 | $9.6B | $12.4B | ||
| Q3 24 | $8.5B | $12.8B | ||
| Q2 24 | $8.2B | $13.4B | ||
| Q1 24 | $8.9B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-916.4M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $-1.2B | $161.8M |
| 自由现金流率自由现金流/营收 | -237.6% | 21.0% |
| 资本支出强度资本支出/营收 | 62.3% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $-3.8B | $509.4M |
8季度趋势，按日历期对齐
经营现金流LCIDRVTY
| Q4 25 | $-916.4M | $182.0M | ||
| Q3 25 | $-756.6M | $138.5M | ||
| Q2 25 | $-830.2M | $134.3M | ||
| Q1 25 | $-428.6M | $128.2M | ||
| Q4 24 | $-533.1M | $174.2M | ||
| Q3 24 | $-462.8M | $147.9M | ||
| Q2 24 | $-507.0M | $158.6M | ||
| Q1 24 | $-516.7M | $147.6M |
自由现金流LCIDRVTY
| Q4 25 | $-1.2B | $161.8M | ||
| Q3 25 | $-955.5M | $120.0M | ||
| Q2 25 | $-1.0B | $115.5M | ||
| Q1 25 | $-589.9M | $112.2M | ||
| Q4 24 | $-824.8M | $149.8M | ||
| Q3 24 | $-622.5M | $125.6M | ||
| Q2 24 | $-741.3M | $136.6M | ||
| Q1 24 | $-714.9M | $129.7M |
自由现金流率LCIDRVTY
| Q4 25 | -237.6% | 21.0% | ||
| Q3 25 | -283.9% | 17.2% | ||
| Q2 25 | -390.4% | 16.0% | ||
| Q1 25 | -251.0% | 16.9% | ||
| Q4 24 | -351.8% | 20.5% | ||
| Q3 24 | -311.2% | 18.4% | ||
| Q2 24 | -369.6% | 19.7% | ||
| Q1 24 | -413.9% | 20.0% |
资本支出强度LCIDRVTY
| Q4 25 | 62.3% | 2.6% | ||
| Q3 25 | 59.1% | 2.6% | ||
| Q2 25 | 70.4% | 2.6% | ||
| Q1 25 | 68.6% | 2.4% | ||
| Q4 24 | 124.4% | 3.4% | ||
| Q3 24 | 79.8% | 3.3% | ||
| Q2 24 | 116.8% | 3.2% | ||
| Q1 24 | 114.7% | 2.7% |
现金转化率LCIDRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | — | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | — | 2.87× | ||
| Q1 24 | — | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LCID
| LCNRV | $287.2M | 55% |
| Other | $80.4M | 15% |
| Related Party | $74.4M | 14% |
| Regulatory Credits | $34.2M | 7% |
| Warranty Provision | $26.2M | 5% |
| Sale And Leaseback Transactions | $15.2M | 3% |
| Other International | $5.0M | 1% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
